With the FDA “locked and loaded,” and billions of annual sales and “deal flow capital” hanging in the balance, the cannabis and hemp industries are questioning whether their products can be manufactured, sold and marketed without vending adulterated or misbranded food, drugs and cosmetics, or making false or unsubstantiated health claims. By Steve Schain Powered […]
FDA
Market Confusion on CBD and Hemp; FDA Commissioner Resigns amid Congressional Pressure for Federal Guidance
By Ian Stewart & Neil Willner The Commissioner of the Food and Drug Administration (FDA), Scott Gottlieb MD, who has received high marks for his leadership of the agency since May 2017, announced his resignation on March 5, 2019, stating that he wants to spend more time with his family. His resignation came only days following […]
Understanding Potential CBD Users; Drivers to Adoption
In recent weeks, this space has seen several contributions from High Yield Insights to the ongoing conversation in the industry on cannabidiol. Dating back to a high-level review of the CBD consumer in July 2018, our approach has to evaluate the opportunities and challenges ahead for CBD through the lens of consumer insights. Most recently, […]
Marijuana gives you the munchies. What about CBD?
As a dietitian, I always receive an influx of New Year’s emails predicting upcoming food trends. This year, several experts have forecast an increase in foods and beverages containing cannabidiol, a chemical compound found in cannabis plants. More colloquially called CBD, cannabidiol has been approved by the FDA to treat some forms of epilepsy and […]
Surgeon General Believes It’s High Time For Marijuana Reclassification
At the close of 2018, the U.S. Surgeon General Jerome Adams made a bold move, and called on the federal government to rethink marijuana’s classification as a Schedule I substance. While the Surgeon General did not go so far as to condone legalization for recreational use, he did say that medically, marijuana should be studied like any […]
Will Hemp-Derived CBD Be Fully Legal with Passage of the 2018 Farm Bill? Not Quite…
By Ian Stewart, Wilson Elser Public interest in the potential health benefits of CBD (cannabidiol) is responsible for a whole new market segment of health and wellness foods and supplements that features CBD as an ingredient. CBD is one of more than 100 cannabinoids in the cannabis plant, but unlike THC (tetrahydrocannabinol), CBD is not […]
FDA Rejects Petition To Further Restrict Marijuana
The U.S. Food and Drug Administration (FDA) has denied a request from an anti-legalization group to place marijuana and its derivatives on a list of restricted substances that are not “generally recognized as safe and effective.” The move is “not necessary for the protection of public health,” Janet Woodcock, the director of FDA’s Center for Drug […]
‘No such thing as medical marijuana,’ Health Secretary says at Dayton-area visit
KETTERING — As Ohio prepares to launch its medical marijuana program by issuing licenses to cultivators, processors and dispensers, U.S. Health and Human Services Secretary Alex Azar said in Kettering today, “There really is no such thing as medical marijuana.” The statement came during a press conference on opioids at Brigid’s Path, an inpatient facility that […]
Cannabis & Sports With Orthopaedic Surgeon Dr. Charles Bush-Joseph
By Shane McCormick It was my good fortune recently to interview Dr. Charles Bush-Joseph. Dr. Bush-Joseph is the team physician for the Chicago White Sox, Associate Team Physician for the Chicago Bulls and he is currently a Professor at Rush University Medical Center as well as the Associate Director of the Rush Orthopaedic Sports Medicine Fellowship […]
Anti-Legalization Big Pharma Company Has Their Synthetic THC Drug Approved By FDA
Insys Therapeutics, a pharmaceutical company that was one of the chief financial backers of the opposition to marijuana legalization in Arizona last year, received preliminary approval from the Drug Enforcement Administration this week for Syndros, a synthetic marijuana drug. Insys gave $500,000 last summer to Arizonans for Responsible Drug Policy, the group opposing marijuana legalization in Arizona. […]
Big Pharma Seeks to Capitalize on Pain-Reducing Compound Derived From Cannabis
The medicinal properties of cannabidiol (better known as CBD), a compound found in the Cannabis sativa L. plant species, are quickly drawing the attention of scientists, plant-medicine lovers, dietary-supplement companies, venture capitalists, professional athletes and Big Pharma — not to mention people living with serious, chronic medical conditions. Insiders predict the burgeoning market will be […]
FDA Approves Insys Therapeutics’ 2nd Cannabis-Based Drug
On June 21, Todd Hagopian recommended Insys Therapeutics (INSY). Since then, the stock has gained nearly 20%. After a stock runs like this, many investors are tempted to sell. However, in situations like this, I’ve found it valuable to know which side of the trade the people with superior track records are on before making any trading […]
U.S. Pharmacopeial Convention: Analyzing the Need for Public Quality Standards for Medical Cannabis
Interesting things are taking place behind the scenes as cannabis prohibition moves to a grinding halt. Key organizations like U.S. Pharmacopeial Convention (USP), a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements manufactured, distributed and consumed worldwide, has begun evaluating the advisability and […]
